Dreilich Martin, Bergqvist Michael, Moberg Martin, Brattström Daniel, Gustavsson Inger, Bergström Stefan, Wanders Alkwin, Hesselius Patrik, Wagenius Gunnar, Gyllensten Ulf
Department of Oncology, University Hospital, 751 85 Uppsala, Sweden.
BMC Cancer. 2006 Apr 18;6:94. doi: 10.1186/1471-2407-6-94.
Human papilloma virus (HPV) in patients with esophageal carcinoma has previously been studied with an average detection rate of 15%, but the role of HPV in relation to survival is less clear. In cervical cancer, lung cancer and tonsil cancer HPV viral load is a predictive factor for survival and outcome of treatment. The primary aim was to study the spectrum of high-risk HPV types in esophageal tumors. Secondary, as a pilot study we investigated the association between HPV status and the survival rates.
We compared both the presence and the viral load of high-risk HPV types 16, 18, 31, 33, 39, 45, 52, 58, and 67 in relation to clinical data from patients with esophageal carcinoma. Survival data and tumor samples were retrieved from 100 patients receiving treatment at the Department of Oncology, Uppsala Hospital, Uppsala, Sweden. The tumor samples were investigated for HPV viral load using real-time PCR.
HPV 16 was detected in 16% of the patients; no other HPV type was detected. HPV 16 infection had no significant effect on survival (p = 0.72). Also, HPV 16 did not improve survival after treatment (radiotherapy or chemotherapy).
Only HPV 16 was detected among the patients. HPV 16 in esophageal carcinoma patients did not influence survival or improve therapy response. However, given the size of the study there is a need to examine a larger cohort in order to understand in more detail the effect of high risk HPV types in esophageal carcinoma.
先前对食管癌患者的人乳头瘤病毒（HPV）进行了研究，平均检出率为15%，但HPV与生存的关系尚不清楚。在宫颈癌、肺癌和扁桃体癌中，HPV病毒载量是生存和治疗结果的预测因素。主要目的是研究食管肿瘤中高危HPV类型的谱。其次，作为一项初步研究，我们调查了HPV状态与生存率之间的关联。
我们比较了高危HPV 16、18、31、33、39、45、52、58和67型的存在情况和病毒载量，并将其与食管癌患者的临床数据相关联。生存数据和肿瘤样本取自瑞典乌普萨拉乌普萨拉医院肿瘤科接受治疗的100名患者。使用实时PCR检测肿瘤样本中的HPV病毒载量。
16%的患者检测到HPV 16；未检测到其他HPV类型。HPV 16感染对生存无显著影响（p = 0.72）。此外，HPV 16在治疗（放疗或化疗）后并未改善生存。
患者中仅检测到HPV 16。食管癌患者中的HPV 16不影响生存或改善治疗反应。然而，鉴于本研究的规模，需要研究更大的队列，以便更详细地了解高危HPV类型在食管癌中的作用。
